After an overview of HL epidemiology and biology in the AYA population, this review will cover frontline pediatric and adult treatment approaches.
One-Alpha* is indicated in all conditions where there is a disturbance of calcium metabolism due to impaired 1-α hydroxylation such as when there is reduced renal function. The main indications are: a) Renal osteodystrophy b) Hyperparathyroidism (with bone disease) c) Hypoparathyroidism d) Neonatal hypocalcaemia e) Nutritional and malabsorptive rickets and osteomalacia f) Pseudo-deficiency (D-dependent) rickets and osteomalacia g) Hypophosphataemic vitamin D resistant rickets and osteomalacia
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL).
Genentech, announced that the Phase III MINISTONE-2 study showed that one-dose Xofluza (baloxavir marboxil) was a well-tolerated and effective potential...
Roche announced that The Lancet has published two papers highlighting one-year results from four pivotal phase III studies of faricimab, an investigational bispecific antibody, in neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Roche announced data from the Phase III OCARINA II study (S31.006) of Ocrevus (ocrevuslizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection
EDAP TMS SA a global leader in therapeutic ultrasound, announced that it has received 510(k) clearance from the FDA for...
Eli Lilly and Company announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, the company's investigational IL-13 inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis (AD).